Related Experiment Video
Updated: Jul 19, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
[Intranasal inactivated influenza vaccine]
1Department for Coordination Program of Science and Technology Projects, Japan Science and Technology Agency.
Abstract:
Natural influenza virus infection is well known to be superior to parenteral inactivated vaccines, which induce serum IgG antibodies(Abs) alone, in inducing the broad-spectrum cross-protection against variant virus infection. Secretory IgA Abs, which provide cross-protection strongly against infection with variant viruses within the same subtype mainly in the upper respiratory tract, serum IgG Abs, which provide cross-protection weakly against infection with variant viruses mainly in the lower respiratory tract, and cytotoxic T lymphocytes, which provide cross-protection against infection with different subtype viruses and whose role is not always big in humans, are involved in the defence mechanisms induced by natural infection. The development of intranasal inactivated vaccine, capable of inducing both IgA and IgG Abs, is important to improve the efficacy of current inactivated vaccine.
More Related Videos
07:33Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
09:31Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
Published on: April 15, 2017
Related Concept Videos
Influenza
Inhibitors Of Virion Release